FDA Panel Endorses Pfizer’s RSV Vaccine for Older Adults

Move comes amid some concerns of Guillain-Barré syndrome

A human respiratory syncytial virus, also known as RSV, shown in a 1981 electron microscope image. Centers for Disease Control and Prevention via AP

A panel of outside advisers to the U.S. Food and Drug Administration (FDA) voted to endorse a vaccine from Pfizer for respiratory syncytial virus (RSV) on Tuesday.

The majority vote to endorse Pfizer’s product brings it closer to potentially becoming the first approved vaccine for RSV for older adults in the United States. The FDA had granted priority review to Pfizer’s application for the vaccine in December 2022.